Every 10-Q that Glaukos Corporation (GKOS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GKOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GKOS filings page.
Glaukos Corporation reported 50% year‑over‑year net sales growth for the quarter ended June 30, 2026, with net sales of $185.6 million versus $124.1 million, and six‑month net sales of $336.2 million versus $230.8 million. Gross margin improved to 82% in Q2 from 78%, helped by higher‑priced iDose TR glaucoma implants and growing Epioxa corneal therapy sales.
Operating expenses rose 41% to $168.9 million, reflecting expanded commercial infrastructure, R&D spending and higher stock‑based compensation, resulting in a Q2 net loss of $18.4 million and a six‑month net loss of $38.2 million. The company held $289.3 million in cash, cash equivalents, short‑term investments and restricted cash, alongside an accumulated deficit of $971.3 million.
Growth was led by U.S. glaucoma revenue (up 64%) and corneal health revenue (up 48%), plus double‑digit international glaucoma growth aided by foreign‑exchange tailwinds. Important updates included a permanent HCPCS J‑code (J2789) for Epioxa effective July 1, 2026, proposed Medicare coverage determinations for iDose TR, and an ongoing commercial transition from Photrexa to Epioxa.
Glaukos Corporation reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net sales rose to $150.6 million from $106.7 million a year earlier, driven mainly by higher U.S. glaucoma revenue from the iDose TR sustained-release implant and growth in international glaucoma procedures.
Corneal health revenue also increased as Photrexa and the early Epioxa launch contributed more U.S. sales. Gross margin was 78%, similar to last year, but higher selling, general and administrative expenses of $92.9 million and research and development spending of $44.1 million kept the company in the red, with a net loss of $19.8 million, or $0.34 per share.
Glaukos ended the quarter with $280.5 million in cash, cash equivalents, short-term investments and restricted cash. The company highlighted an option agreement for potential new drug technology and noted a permanent HCPCS J-code for Epioxa effective July 2026, which is expected to simplify U.S. reimbursement for its new keratoconus therapy.
Glaukos Corporation reported Q3 2025 results. Net sales were $133.5 million for the three months ended September 30, 2025, up from $96.7 million a year ago, while net loss narrowed to $16.2 million with basic and diluted net loss per share of $0.28.
Glaucoma products contributed $110.2 million and Corneal Health $23.3 million in the quarter. Gross profit was $104.7 million; operating expenses were $121.1 million, leading to a loss from operations of $16.4 million. Cash and cash equivalents were $98.2 million and short‑term investments $175.5 million at quarter‑end. Total assets were $999.4 million and stockholders’ equity was $769.5 million.
Year to date, net sales reached $364.3 million versus $278.0 million last year, with net loss of $54.0 million. The company closed the Mobius Therapeutics acquisition with $24.5 million consideration and purchased an adjacent Aliso Viejo building for $16.6 million. Accounts receivable rose, driven by iDose TR’s extended payment terms. Shares outstanding were 57,434,740 as of October 29, 2025.